Association between ranolazine therapy and cognitive decline in elderly patients with ischemic heart disease.

ABSTRACT:

Introduction

Ischemic Heart Disease (IHD) represents one of the major causes of mortality and morbidity in the geriatric population This clinical complexity of these patients substantially impacts their quality of life and is associated with an increased risk of cognitive impairment (CoI). Ranolazine, plays a pivotal role in managing anginal symptoms and improving exercise tolerance.

Objective

To investigate the potential protective effect of Ranolazine on CoI over time in elderly patients with IHD and multiple comorbidities.

Methods

We performed a single-center, prospective, observational cohort study. The primary endpoint was a reduction in MMSE score ≥3 points during follow-up compared to baseline values.

Results

519 patients with a mean age of 74.2 ± 6.8 ye

SUBMITTER: Severini G 

PROVIDER: S-EPMC12698426 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature